Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJOncoAlert Journal Club | Dose-escalated radiation vs. conventionally fractionated radiation for localized PC

Comron Hassanzadeh • 5 Jun 2025
VJOncoAlert Journal Club
Genitourinary Cancer Prostate Cancer

In this latest episode of the VJOncoAlert Journal Club, Comron Hassanzadeh, MD, MPH, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses long-term results of hypofractionated, dose-escalated radiation versus conventionally fractionated radiation for patients with localized prostate cancer. While earlier results indicated a benefit in treatment failure for hypofractionated radiation, this advantage is no longer statistically significant at the 13-year mark, though a trend remains.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Comron Hassanzadeh

Evaluating the emerging role of MDT in bladder cancer
1:58
Evaluating the emerging role of MDT in bladder cancer
Comron Hassanzadeh • 6 Mar 2025
The role of XRT in isolated pelvic recurrences after RC in bladder cancer
3:14
The role of XRT in isolated pelvic recurrences after RC in bladder cancer
Comron Hassanzadeh • 6 Mar 2025
Metastasis-directed radiotherapy in oligometastatic urothelial cancer
3:11
Metastasis-directed radiotherapy in oligometastatic urothelial cancer
Comron Hassanzadeh • 6 Mar 2025

Related Videos

Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
3:04
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
Andrew Armstrong • 3 Jun 2026
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
2:24
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
Andrew Armstrong • 3 Jun 2026
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals